|View printer-friendly version|
|Quidel Announces Urinalysis Automated Analyzer Now Available Worldwide|
|Düsseldorf, Germany (November 20, 2002) – Quidel Corporation (Nasdaq: QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, raised the bar in urinalysis testing with the announcement of the worldwide availability of its state-of-the-art urinalysis instrument, the UrinQuick® Urine Chemistry Analyzer. The announcement was made at the MEDICA 34th World Forum for Medicine in Düsseldorf, Germany, the largest global meeting for medical suppliers to spotlight their latest advancements, top concepts and best-selling products.
The UrinQuick™ Urine Chemistry Analyzer provides advanced software capabilities and newly patented transport and optic systems. Extremely user-friendly screens guide laboratory personnel through every aspect of operation, including a full on-board quality control program, a first for an instrument of this class. It also has the added benefit of automating the reading of Quidel's QuickVue® UrinChek® test strips, thereby enabling the practitioner to make timely patient management decisions to aid in the diagnosis of diabetes, liver and kidney disease, urinary tract infections and other health parameters.
“The UrinQuick™ Urine Chemistry Analyzer is a new state-of-the-art instrument that supports the growing global demand for our urine test strips,” said S. Wayne Kay, president and chief executive officer of Quidel. “It is very rewarding for us to be able to provide diagnostic tools such as the UrinQuick™ in direct response to pressing market needs. Orders have already been placed from approximately 15 countries. By broadening this product's availability into European and Asia/Pacific markets, we believe we can significantly expand our worldwide position in this $430 million urinalysis testing market.”
Quidel Corporation, a worldwide company helping women and their families live healthy lives, discovers, develops, manufactures and markets rapid point-of-care diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions associated with women's health in areas such as reproduction and diseases of the elderly. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, Strep throat, H. pylori infection, chlamydia, infectious mononucleosis and infectious vaginitis. Quidel's products are sold to healthcare professionals for use in physician offices, clinical laboratories and pharmacies, and to consumers through organizations that provide private label, store brand products. These tests provide diagnostic information that enables rapid treatment and improves health outcomes, lowers costs and increases patient satisfaction. For more information, please visit Quidel's Web site at http://www.quidel.com.
This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risk and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially. As such, no forward-looking statement can be guaranteed. Differences in operating results may arise as a result of a number of factors including, without limitation, seasonality, adverse changes in the competitive and economic conditions in domestic and international markets, actions of our major distributors, manufacturing and production delays or difficulties, adverse actions or delays in product reviews by the FDA and the lower acceptance of our new products than forecast. Forward-looking statements typically are identified by the use of terms such as “may,” “will,” “should,” “might,” “expect,” “anticipate,” “estimate” and similar words, although some forward-looking statements are expressed differently. The risks described under “Risk Factors” and in other sections of our Form 10-K for year ended December 31, 2001, and in other reports and registration statements that we file with the Securities and Exchange Commission from time to time should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this presentation. We undertake no obligation to publicly release the results of any revision of the forward-looking statements.
Contact:Lippert/Heilshorn & Associates
Ina McGuinness (firstname.lastname@example.org)
Bruce Voss (email@example.com)
Paul E. Landers
Vice President & CFO